Nanhua Bio-medicine Co., Ltd. (SZ: 000504, share price 12.11 yuan, market cap 3.997 billion yuan) released a stock trading risk warning announcement on the evening of September 22. The company's shares have closed at the daily limit up for four consecutive trading days from September 17 to September 22, with a cumulative gain of 46.43% during that period. The company stated that its main business is biopharmaceuticals and energy conservation and environmental protection, and its cell therapy-related technologies and products are still in the research and development stage, with no innovative drugs launched or entering clinical trials.

The announcement from Nanhua Bio-medicine revealed that the stock has hit the daily limit up for four consecutive sessions, and the price-to-earnings ratio (TTM) stands at approximately 104.33 times. The company noted that the short-term surge in stock price indicates possible overheating of market sentiment and characteristics of irrational speculation, and does not rule out the possibility of significant price fluctuations in the future.

The announcement also disclosed that the listed company's main business consists of two segments: biopharmaceuticals and energy conservation and environmental protection. In the biopharmaceutical segment, the company primarily provides testing and storage services for biological resources such as stem cells and immune cells, while also collaborating with multiple clinical research institutions to offer cell preparation and testing services that meet clinical research requirements. The company's cell therapy-related technologies and products are still in the R&D phase, with no innovative drugs launched or entering clinical trials. The energy conservation and environmental protection segment mainly engages in lithium carbonate business, scrap steel recycling resources, and related processing and sales operations.

Additionally, the company's previously planned major asset restructuring to acquire a 51% equity stake in Hunan Huize Biomedical Technology Co., Ltd. was terminated on January 22, 2026, and the company currently has no CRO business. The company indicated that recent operating conditions and internal and external business environments have not undergone major changes, and there are currently no matters that should be disclosed but have not been disclosed according to the Shenzhen Stock Exchange's "Stock Listing Rules" and other relevant regulations.

The company also warned that if the stock's liquidity does not meet expectations, investors buying or selling the stock may face risks of delayed transactions or prices deviating from expectations. It reminded investors to pay attention to secondary market trading risks, make rational decisions, invest prudently, and avoid blindly following speculative trends.

According to the "2026 Semi-Annual Report" released by Nanhua Bio-medicine on August 23, the company's main business comprises two segments: biopharmaceuticals and energy conservation and environmental protection. The biopharmaceutical segment primarily provides testing and storage services for biological resources such as stem cells and immune cells. The energy conservation and environmental protection segment mainly engages in lithium carbonate business, scrap steel recycling resources, and related processing and sales operations.

In terms of financial performance, in the first half of 2026, the company achieved operating revenue of 296 million yuan, a year-on-year increase of 473.56%. Net profit attributable to shareholders of the listed company was 5.9927 million yuan, a year-on-year increase of 271.99%, compared to a loss of 3.4844 million yuan in the same period last year. Net profit after deducting non-recurring gains and losses was 4.317 million yuan, up 164.86% year-on-year. Basic earnings per share were 0.0182 yuan.

During the reporting period, the increase in operating revenue was mainly attributed to higher income from the energy-saving industry and lithium carbonate business. By industry segment, the lithium carbonate industry generated revenue of 154 million yuan, accounting for 51.89% of total operating revenue, making it the company's largest revenue source. The energy-saving technology service industry generated revenue of 96.6505 million yuan, accounting for 32.66%. The biopharmaceutical industry generated revenue of 45.0873 million yuan, accounting for 15.24%.

In terms of stock price, Nanhua Bio-medicine has shown an overall upward trend this year, with data indicating a cumulative gain of approximately 35.31% from the beginning of the year to date.

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Any actions taken based on this information are at your own risk.